Welcome to our dedicated page for Materialise SEC filings (Ticker: MTLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Materialise NV files as a foreign private issuer, and its SEC reports document financial results, capital actions, and corporate disclosures for its additive manufacturing software, medical, and manufacturing businesses. Form 6-K reports include quarterly result releases, segment revenue for Materialise Medical, Materialise Software, and Materialise Manufacturing, expense categories such as R&D, sales and marketing, and general and administrative costs, cash balances, and exhibits incorporated by reference into a Form F-3 registration statement.
The company’s filings also cover Belgian-law annual report materials, share buyback program updates, treasury-share holdings, exchange execution details, and share-capital disclosures tied to its Nasdaq ADSs and Euronext-listed ordinary shares.
Materialise NV provided an update on its ongoing share buy-back program of up to EUR 30 million. Between 11 and 15 May 2026, the company repurchased 74,816 shares at an average price of 4.77 EUR, for a total of 356,986 EUR.
Since the program began on 26 January 2026, Materialise has bought back 748,789 shares for 3,399,426 EUR (3,999,747 USD), representing about 1.3% of its outstanding shares. All recent purchases were executed on Nasdaq via the central order book, with no cross or block trades.
Materialise NV reports modest top-line growth but weaker earnings for 2025 and sets its annual shareholders’ meeting for 16 June 2026. Consolidated revenue edged up 0.3% to €267.6 million, while net profit fell to €7.7 million from €13.4 million, mainly due to higher financial expenses driven by unfavorable foreign exchange movements.
The Materialise Medical segment was the main growth driver, with revenue rising 15.4% to €134.2 million and an adjusted EBITDA margin of 32.0%. Software revenue declined 6.8% to €40.9 million as the business transitions to cloud and subscription models, although its adjusted EBITDA margin improved to 13.4%. Manufacturing revenue dropped 13.2% to €92.5 million, pushing adjusted EBITDA to a loss of €4.2 million.
On the balance sheet, total assets increased to €420.6 million, equity attributable to owners rose to €255.6 million, and cash and cash equivalents climbed to €133.9 million, alongside higher loans and borrowings of €57.5 million. Management highlights that internal control weaknesses identified in 2024 were fully remediated in 2025 and that disclosure controls and procedures were deemed effective as of 31 December 2025. The group also completed the sale of its RapidFit business assets at carrying value, with no material profit or loss expected.
Materialise NV provides an update on its share buy-back program. The company repurchased 44,893 shares between 4 and 8 May 2026 at an average price of 4.67 EUR, for a total of 209,653 EUR.
Since the program began on 26 January 2026, Materialise has bought back 673,973 shares for 3,042,441 EUR (3,581,452 USD), equal to 1.1% of total shares outstanding. The company currently holds these 673,973 shares and continues to report weekly progress on its investor website.
Materialise NV reported stable revenue but a clear profitability improvement in the first quarter of 2026. Total revenue was 66,276 kEUR, essentially flat versus 66,379 kEUR a year earlier, but gross margin rose to 57.2% from 55.3%.
Net profit improved to 1,820 kEUR, compared to a net loss of 535 kEUR in 2025, helped by a stronger net financial result and higher gross profit. Adjusted EBITDA increased to 8,049 kEUR from 6,147 kEUR, lifting the Adjusted EBIT margin to 3.7% from 1.0%.
The Materialise Medical segment grew revenue 6.7% to 33,165 kEUR, while Software dipped 1.4% and Manufacturing fell 8.1%. All three segments showed higher Adjusted EBITDA, with Manufacturing moving from a loss to a small profit. The company ended March 31, 2026 with 132,952 kEUR in cash and a net cash position of 72,826 kEUR and had repurchased 511,513 shares for 2,308 kEUR. After quarter-end, Materialise agreed to transfer its eyewear business to its management team and expects to record impairment charges in the second quarter of 2026.
Materialise NV reported first quarter 2026 revenue of 66,276 kEUR, essentially flat year over year, but turned to a net profit of 1,820 kEUR from a loss of 535 kEUR. Adjusted EBIT rose to 2,470 kEUR, a 3.7% margin versus 1.0% a year earlier, and Adjusted EBITDA increased to 8,049 kEUR.
Medical revenue grew 6.7% to 33,165 kEUR, while Software declined slightly and Manufacturing fell 8.1%, though both segments improved profitability. Gross margin expanded to 57.2%. The company ended the quarter with 132,952 kEUR in cash, a 72,826 kEUR net cash position, and positive free cash flow.
Materialise agreed to transfer its eyewear business to its management team, retaining a minority stake and expecting impairment charges in the second quarter of 2026. Despite the Rapidfit and Eyewear divestments, the company reaffirmed its 2026 revenue guidance of 273,000–283,000 kEUR and Adjusted EBIT guidance of 10,000–12,000 kEUR.
Materialise NV reports progress on its ongoing share buy-back program. During 27 April to 1 May 2026, the company repurchased 27,493 shares at an average price of 4.54 EUR per share, for a total of 124,826 EUR.
Since the program started on 26 January 2026, Materialise has bought back 629,080 shares for 2,832,788 EUR (3,335,311 USD), equal to 1.1% of its total shares outstanding. The company currently holds these 629,080 shares and may continue repurchases under its mandate of up to 30 million EUR.
Materialise NV reports progress on its ongoing share buy-back program of up to EUR 30 million. Between 20 and 24 April 2026, the company repurchased 25,004 shares on Nasdaq at an average price of EUR 4.56, for a total of EUR 114,106.
Since the program began on 26 January 2026, Materialise has bought back 601,587 shares for EUR 2,707,962 (about USD 3,189,210), equal to 1% of total shares outstanding. The company now holds these 601,587 shares as its own stock and plans to keep updating buy-back data weekly on its investor website.
Materialise NV, a Belgium-based 3D printing and software company, files its annual report outlining how it runs and grows its additive manufacturing business across software, medical and manufacturing segments. The report emphasizes dependence on broader adoption of 3D printing, the shift from on-premise licenses to cloud and SaaS platforms, and heavy exposure to automotive, aerospace and orthopedic markets, which together drive 40% of annual turnover.
Materialise highlights reliance on collaborations with major medical device companies, substantial ongoing R&D and AI/ML investments, and intensifying competition as barriers to entry fall. It details operational and cybersecurity risks as it moves more products to cloud delivery, and notes that only 2.3% of revenue is generated in Belgium while international operations, including more than 400 staff in Kyiv, Ukraine, expose it to geopolitical and macroeconomic shocks. The company also underscores regulatory complexity in its medical segment, including EU Medical Device Regulation, FDA rules, GDPR, HIPAA and emerging AI and ESG requirements, any of which could increase costs or restrict growth.
Materialise NV reports progress on its ongoing share buy-back program of up to EUR 30 million. Between 13 and 17 April 2026, the company repurchased 31,054 shares at an average price of EUR 4.45, for a total of EUR 138,089, via Nasdaq.
Since the program began on 26 January 2026, Materialise has bought back 576,583 shares for EUR 2,593,856 (USD 3,055,313), equal to about 1% of total shares outstanding. All repurchases were executed through the central order book, with no cross or block trades.